DYN Similar Chart Price Prediction
The price of DYN is predicted to go up -12.5%, based on the high correlation periods with TRX. The similarity of these two price pattern on the periods is 95.3%.
DYN
TRX
Down: -12.5%Similarity: 95.3%
DYN Revenue Forecast
DYN EPS Forecast
DYN FAQs
What is DYN eps forecast for next quarter？
DYN Analyst's Forecast
Luca Issi
RBC Capital
Buy
2025-01-14
Price Target
$45
Upside
+200%
RBC Capital notes that Dyne Therapeutics announced new clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER Phase 1/2 trial designed to study the safety and efficacy of DYNE-251 in patients with Duchenne Muscular Dystrophy who are amenable to exon 51 skipping. While acknowledging that the high dose is "clearly not game changing" and that the splicing data at six months "will raise some eyebrows," the firm remain buyers as RBC likes the clean safety and consistent data showing solid muscle uptake and an improvement in both splicing and function. The firm keeps an Outperform rating and $45 price target on shares of Dyne, which are down $5.25, or 23%, to $17.80 in Friday late morning trading.
Brian Skorney
Baird
Buy
2024-12-13
Price Target
$46
Upside
+76.25%
Luca Issi
RBC Capital
Buy
2024-11-26
Price Target
$45
Upside
+53.95%
